Important legal notice
Contact   |   Search on Europa   

Infectious Diseases Graphic element print icon Graphic element
  Homepage
Graphic element General information
  RTD Infectious Diseases Unit
  Developing countries
  EDCTP
   
Graphic element Projects
  About FP6 Funding
  FP6 projects
  About FP5 Funding
  FP5 projects
   
   
Graphic element Addressed Diseases
  HIV/AIDS
- News
  Malaria
  Tuberculosis
   
Graphic element Calls for proposals
  FP7 Calls
   
Graphic element Contact corner
  Unit
  Scientific officers
  Subscribe to our mailing list
   
 
EMVI
STRATEGIC SUPPORT MEASURES (INCO)
Framework programme: 5
Project number:
ICC1-CT-2002-50001
EC contribution: € 700 000
Duration: 36 months
Type: AM
Starting date: 1 August 2002
Graphic element European Malaria Vaccine Initiative

Summary:

To contribute to the European Commission's Accelerated Action for Control of the Poverty Related Diseases by sustaining and expanding a European Clinical Trials and Development Platform for Malaria vaccines, enabling co-ordination of EC and EU efforts. To ensure international co-ordination and collaboration in malaria vaccines development and testing. To put in place a structure needed to ensure rapid and flexible reaction to technological and scientific breakthroughs in malaria vaccine development. To provide a mechanism for EU Member States' financial contributions towards achieving the common goal of developing affordable and accessible vaccines in endemic areas.

Objectives:

The objectives of this project are:

1) to contribute to the European Commission's Accelerated Action for Control of the Poverty Related Diseases by sustaining and expanding a European clinical trials and development platform for malaria vaccines, enabling coordination of EC and EU efforts
2) to ensure international coordination and collaboration in malaria vaccine development and testing
3) to put in place a structure that is needed to ensure rapid and flexible reaction to technological and scientific breakthroughs in malaria vaccine development
4) to provide a mechanism for EU Member States' financial contributions towards achieving the common goal of developing affordable and accessible vaccines in endemic areas.

Description:

The EMVI secretariat proposes to manage the development of candidate malaria vaccines within the EU by creating a pipeline from GMP manufacture to clinical trials in the EU, and to clinical trials in Africa together with AMVTN. The main aims are:

1) the evaluation of proposals, by the EMVI scientific advisory committee (SAC), from EU research institutions for the GMP manufacture of clinical grade candidate malaria vaccines
2) the creation and management of product development teams to oversee GMP manufacture
3) the creation and management of clinical trials and development teams to oversee the phase I, and possibly phase II, clinical trials in Europe. This also involves the development of clinical protocols
4) the management of the SAC for GMP/clinical trial applications and evaluations to decide whether vaccine candidates should be advanced to clinical trials in Africa with AMVTN
5) together with AMVTN, and/or other international bodies, the management of clinical trials in one or more sites within Africa
6) the data management of the GMP manufacture and clinical trials
7) the negotiation and management of the financial contracts supporting these activities
8) the development of contracts with EU Member State's research councils for financial support to fund these activities
9) the development of vaccine initiatives with other EU and international agencies to support a global approach to malaria vaccines, as supported, for example, by the Memoranda of Understanding
10) the preparation of reports on all these activities to the EMVI Board, and attendance at the EMVI Board Meetings.

Milestones:

EMVI will appoint the manager, deputy manager and finance/office manager upon initiation of the award. During the contract, the secretariat will manage the GMP manufacture of up to ten candidate vaccines, and advance these through clinical trials in Europe. It will manage collaboration with AMVTN on clinical site strengthening, and the clinical trials of six candidate malaria vaccines, with the expectation that one candidate vaccine will enter expanded efficacy trials by the end of the contract.

Coordinator:

Soeren Jepsen
Statens Serum Institut,
Office of International Health
Statens Serum Institut Artillerivej 5
2300 Copenhagen S, Denmark
Tel: +45 32 683188
Fax: +45 31 683228
E-mail: sje@ssi.dk

Partners:

  1. European Malaria Vaccine Inititiative - Centre for International Health, University of Bergen, Bergen, Norway

 
 
top
Graphic element